XP 23829

Drug Profile

XP 23829

Alternative Names: Methylhydrogenfumarate prodrug - Arbor Pharmaceuticals; XP23829

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XenoPort
  • Class Anti-inflammatories; Antipsoriatics; Fumarates; Small molecules
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Parkinson's disease; Plaque psoriasis

Most Recent Events

  • 28 Mar 2016 XP 23829 licensed to Dr. Reddy's Laboratories in the US
  • 15 Sep 2015 Interim adverse events and efficacy data from a phase-II trial in Plaque psoriasis released by XenoPort
  • 23 Jun 2014 Phase-II clinical trials in Plaque psoriasis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top